Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07112378 · ClinicalTrials.gov registry record · Phase 3
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
A Phase 3 study of Eosinophilic Esophagitis (EoE), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 6
- Study locations
NCT07112378: Recruiting Phase 3 study of Eosinophilic Esophagitis (EoE), sponsored by Regeneron Pharmaceuticals.
NCT07112378 is a Phase 3 study of Eosinophilic Esophagitis (EoE) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 20 participants, below the 124-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (84% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07112378, a Phase 3 study of Eosinophilic Esophagitis (EoE), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG dupilumab
Study Locations (6)
Arizona
- Phoenix Childrens Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- GI Care for Kids LLC - Atlanta
New York
- Weill Cornell Medicine - New York
North Carolina
- University of North Carolina, Bioinformatics Building - Chapel Hill
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2028-10-09 |
| Phase | Phase 3 |
What NCT07112378 shows while recruiting
NCT07112378 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 124-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Eosinophilic Esophagitis (EoE) appearing as the primary indexed condition, and to 1 intervention - of which dupilumab is the first listed.
NCT07112378 lists 6 locations in 6 states (Arizona, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT07112378 about?
NCT07112378 is a clinical study titled "A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis". This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and...
What is the current status of trial NCT07112378?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2025-11-10. Estimated completion is 2028-10-09.
What conditions does trial NCT07112378 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis (EoE).
What interventions are being tested in trial NCT07112378?
The interventions under investigation include: dupilumab (DRUG).
Who is sponsoring clinical trial NCT07112378?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07112378 being conducted?
This trial has 6 study locations across Arizona, Colorado, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis (EoE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07112378's enrollment target sits among peer trials
20 11th of 10 the lowest of 10 other Eosinophilic Esophagitis (EoE) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis (EoE) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
-
An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
-
Surface EMG Testing on Swallowing in EoE Patients
RECRUITING
-
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
RECRUITING
-
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
RECRUITING · Phase 4
-
Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI